Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Diabetes Care [TA])
16,448 results
  • Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. [Journal Article]
  • DCDiabetes Care 2018 Jun 14
  • Zinman B, Marso SP, … LEADER Publication Committee on behalf of the LEADER Trial Investigators
  • CONCLUSIONS: Patients experiencing severe hypoglycemia were at greater risk of CV events and death, particularly shortly after the hypoglycemic episode. While causality remains unclear, reducing hypoglycemia remains an important goal in diabetes management.
  • Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. [Journal Article]
  • DCDiabetes Care 2018 Jun 14
  • Schrieks IC, Nozza A, … Schwartz GG
  • CONCLUSIONS: In contrast to prior observational data for incident CHD, adiponectin is prospectively associated with MACEs and death in patients with type 2 diabetes and ACS, and an increase in adiponectin from baseline is directly related to death. These findings raise the possibility that adiponectin has different effects in patients with type 2 diabetes and ACS than in populations without prevalent cardiovascular disease. Consistent with prior data, FFAs are directly associated with adverse outcomes.
  • Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. [Journal Article]
  • DCDiabetes Care 2018 Jun 13
  • Nauck MA, Jensen TJ, … LEADER Publication Committee on behalf of the LEADER Trial Investigators
  • CONCLUSIONS: LEADER was not primarily designed to assess neoplasm risk. Firm conclusions cannot be made regarding numeric imbalances observed for individual neoplasm types (e.g., pancreatic cancer) that occurred infrequently. LEADER data do, however, exclude a major increase in the risk of total malignant neoplasms with liraglutide versus placebo. Additional studies are needed to assess longer-term exposure.
  • Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors. [Journal Article]
  • DCDiabetes Care 2018 Jun 13
  • Klonoff DC, Parkes JL, … Kohn MA
  • CONCLUSIONS: Cleared BGMs do not always meet the level of analytical accuracy currently required for regulatory clearance. This information could assist patients, professionals, and payers in choosing products and regulators in evaluating postclearance performance.
New Search Next